This is an aggregated industry headline. Read the full story at Endpoints News →
Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests
While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as ...
By Endpoints News
· Apr 17, 2026
· via Endpoints News
Image: Endpoints News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w…
The WeekFierceBiotech ↗
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Thera…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…